- Home
- OTLK vs MAXN Comparison
OTLK vs MAXN Comparison
Compare OTLK & MAXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- MAXN
- Stock Information
- Founded
- OTLK 2010
- MAXN 2019
- Country
- OTLK United States
- MAXN Singapore
- Employees
- OTLK N/A
- MAXN N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- MAXN Semiconductors
- Sector
- OTLK Health Care
- MAXN Technology
- Exchange
- OTLK Nasdaq
- MAXN Nasdaq
- Market Cap
- OTLK 42.8M
- MAXN 45.2M
- IPO Year
- OTLK 2016
- MAXN N/A
- Fundamental
- Price
- OTLK $1.69
- MAXN $2.86
- Analyst Decision
- OTLK Buy
- MAXN Sell
- Analyst Count
- OTLK 5
- MAXN 1
- Target Price
- OTLK $5.25
- MAXN $4.00
- AVG Volume (30 Days)
- OTLK 4.5M
- MAXN 87.6K
- Earning Date
- OTLK 12-26-2025
- MAXN 11-14-2025
- Dividend Yield
- OTLK N/A
- MAXN N/A
- EPS Growth
- OTLK N/A
- MAXN N/A
- EPS
- OTLK N/A
- MAXN N/A
- Revenue
- OTLK $1,505,322.00
- MAXN $176,414,000.00
- Revenue This Year
- OTLK N/A
- MAXN $100.37
- Revenue Next Year
- OTLK $342.80
- MAXN $24.61
- P/E Ratio
- OTLK N/A
- MAXN N/A
- Revenue Growth
- OTLK N/A
- MAXN N/A
- 52 Week Low
- OTLK $0.79
- MAXN $2.49
- 52 Week High
- OTLK $5.18
- MAXN $9.66
- Technical
- Relative Strength Index (RSI)
- OTLK 59.10
- MAXN 38.56
- Support Level
- OTLK $1.76
- MAXN $2.56
- Resistance Level
- OTLK $2.02
- MAXN $3.73
- Average True Range (ATR)
- OTLK 0.20
- MAXN 0.26
- MACD
- OTLK 0.04
- MAXN -0.05
- Stochastic Oscillator
- OTLK 59.38
- MAXN 30.08
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About MAXN Maxeon Solar Technologies Ltd.
Maxeon Solar Technologies Ltd is engaged in the manufacturing and marketing of premium solar technology. It owns and operates solar cell and panel manufacturing facilities located in Malaysia, Mexico, and the Philippines. The company's primary products are the Maxeon line of interdigitated back contact (IBC) solar cells and panels, and the Performance line (formerly, P-Series) of shingled solar cells and panels. the Maxeon line of solar panels are the highest-efficiency solar panels on the market with an aesthetically pleasing design, and the Performance line of solar panels offers a high-value and cost-effective solution. It is targeted at residential and small-scale commercial customers across the globe. The company derives its revenue from the United States, Italy, and Rest of world.